High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy

Clinical Infectious Diseases

Volumn 58, Issue 7, 2014, Pages 1023-1026

  Gupta, Ravindra K ^a   Goodall, Ruth L ^a   Ranopa, Michael ^a   Kityo, Cissy ^b   Munderi, Paula ^c   Lyagoba, Fred ^c   Mugarura, Lincoln ^b   Gilks, Charles F ^d   Kaleebu, Pontiano ^c   Pillay, Deenan ^a,e   Grosskurth, H ^f,o   Munderi, P ^f   Kabuye, G ^f   Nsibambi, D ^f   Kasirye, R ^f   Zalwango, E ^f   Nakazibwe, M ^f   Kikaire, B ^f   Nassuna, G ^f   Massa, R ^f   Fadhiru, K ^f   Namyalo, M ^f   Zalwango, A ^f   Generous, L ^f   Khauka, P ^f   Rutikarayo, N ^f   Nakahima, W ^f   Mugisha, A ^f   Todd, J ^f   Levin, J ^f   Muyingo, S ^f   Ruberantwari, A ^f   Kaleebu, P ^f,m   Yirrell, D ^f,m   Ndembi, N ^f   Lyagoba, F ^f,m   Hughes, P ^f   Aber, M ^f   Lara, A Medina ^f   Foster, S ^f,n   Amurwon, J ^f,n   Wakholi, B Nyanzi ^f,n   Mugyenyi, P ^b,o   Kityo, C ^b   Ssali, F ^b   Tumukunde, D ^b   Otim, T ^b   Kabanda, J ^b   Musana, H ^b   Akao, J ^b   Kyomugisha, H ^b   Byamukama, A ^b   Sabiiti, J ^b   Komugyena, J ^b   Wavamunno, P ^b   Mukiibi, S ^b   Drasiku, A ^b   Byaruhanga, R ^b   Labeja, O ^b   Katundu, P ^b   Tugume, S ^b   Awio, P ^b,m   Namazzi, A ^b   Bakeinyaga, G T ^b   Katabira, H ^b   Abaine, D ^b   Tukamushaba, J ^b   Anywar, W ^b   Ojiambo, W ^b   Angweng, E ^b   Murungi, S ^b   Haguma, W ^b   Atwiine, S ^b   Kigozi, J ^b,n   Latif, A ^g,o   Hakim, J ^g,o   Robertson, V ^g,m   Reid, A ^g   Chidziva, E ^g   Bulaya Tembo, R ^g   Musoro, G ^g   Taziwa, F ^g   Chimbetete, C ^g   Chakonza, L ^g   Mawora, A ^g   Muvirimi, C ^g   Tinago, G ^g   Svovanapasis, P ^g   Simango, M ^g   Chirema, O ^g   MacHingura, J ^g   Mutsai, S ^g   Phiri, M ^g   Bafana, T ^g   Chirara, M ^g,m   Muchabaiwa, L ^g,n   Muzambi, M ^g,n   Katabira, E ^h,q   Ronald, A ^h   Kambungu, A ^h   Lutwama, F ^h   Nanfuka, A ^h   Walusimbi, J ^h   Nabankema, E ^h   Nalumenya, R ^h   Namuli, T ^h   Kulume, R ^h   Namata, I ^h   Nyachwo, L ^h   Florence, A ^h   Kusiima, A ^h   Lubwama, E ^h   Nairuba, R ^h   Oketta, F ^h   Buluma, E ^h   Waita, R ^h   Ojiambo, H ^h   Sadik, F ^h   Wanyama, J ^h   Nabongo, P ^h   Ochai, R ⁱ   Muhweezi, D ⁱ   Gilks, C ^j,m,o   Boocock, K ^j   Puddephatt, C ^j   Winogron, D ^j   Bohannon, J ^j   Darbyshire, J ^k,o   Gibb, D M ^k,m   Burke, A ^k   Bray, D ^k   Babiker, A ^k,o   Walker, A S ^k   Wilkes, H ^k   Rauchenberger, M ^k   Sheehan, S ^k   Peto, L ^k   Taylor, K ^k   Spyer, M ^k,m   Ferrier, A ^k   Naidoo, B ^k   Dunn, D ^k,m   Goodall, R ^k,m   Nanfuka, R ^l   Mufuka Kapuya, C ^l   Pillay, D ^m   Kapaata, A ^m   Katuramur, M ^m   Magala, R ^m   Magambo, B ^m   Mataruka, K ^m   McCormick, A ^m   Mugarura, L ^m   Musunga, T ^m   Nabankkema, M ^m   Nkalubo, J ^m   Nkurunziza, P ^m   Parry, C ^m   Medina Lara, A ⁿ   Weller, I ^o   Bahendeka, S ^o   Bassett, M ^o   Wapakhabulo, A Chogo ^o   Gazzard, B ^o   Mapuchere, C ^o   Mugurungi, O ^o   Burke, C ^r   Jones, S ^r   Newland, C ^r   Rahim, S ^r   Rooney, J ^r   Smith, M ^r   Snowden, W ^r   Steens, J M ^r   Breckenridge, A ^p   McLaren, A ^p   Hill, C ^p   Matenga, J ^p   Pozniak, A ^p   Serwadda, D ^p   Peto, T ^q   Palfreeman, A ^q   Borok, M ^q   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^c UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e UNIVERSITY OF KWAZULU NATAL   (South Africa)

^f MEDICAL RESEARCH COUNCIL   (United Kingdom)

^g UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^h MAKERERE UNIVERSITY   (Uganda)

ⁱ AIDS Support Organisation   (Uganda)

^j IMPERIAL COLLEGE LONDON   (United Kingdom)

^k MRC CLINICAL TRIALS UNIT   (United Kingdom)

^l Independent DART Trial Monitors   (United Kingdom)

^m DART Virology Group   (United Kingdom)

ⁿ DART Health Economics Group   (United Kingdom)

^o Trial Steering Committee   (United Kingdom)

^p Safety and Data Monitoring Committee   (United Kingdom)

^q Endpoint Review Committee   (United Kingdom)

^r NONE

more..

Author keywords

Africa; Failure; HIV; Resistance; Viral resuppression

Indexed keywords

ABACAVIR; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG COMBINATION; LAMIVUDINE; ZIDOVUDINE;

ANTIVIRAL THERAPY; ARTICLE; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; UGANDAN; VIRUS LOAD; DRUG COMBINATION; DRUG EFFECTS; VIREMIA;

ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DRUG COMBINATIONS; HUMANS; LAMIVUDINE; NEVIRAPINE; VIRAL LOAD; VIREMIA; ZIDOVUDINE;

EID: 84985918673     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit933     Document Type: Article

References (18)

1. Mermin J, Were W, Ekwaru JP, et al. Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIVuninfected children: a prospective cohort study. Lancet 2008; 371:752-9.
2. Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural Kwa-Zulu-Natal, South Africa. Science 2013; 339:966-71.
3. United Nations Joint Programme on HIV/AIDS. Global update on HIV treatment 2013. Available at: http://www.unaids.org/en/media/unaids/ contentassets/documents/unaidspublication/2013/20130630-treat ment-report-summary-en.pdf. Accessed 17 July 2013.
4. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Available at: http://www.who.int/hiv/pub/guidelines/arv2013/download/en/index. html. Accessed 14 July 2013.
5. Mugyenyi P, Walker AS, Hakim J, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 2010; 375:123-31.
6. Ndembi N, Goodall RL, Dunn DT, et al. Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. J Infect Dis 2009; 201: 106-13.
7. Munderi P, Walker AS, Kityo C, et al. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/ zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts. HIV Med 2010; 11:334-44.
8. DART Trial Team. Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/microl. AIDS 2008; 22:237-47.
9. Johnson VA, Calvez V, Gunthard HF, et al. 2013. Update of the drug resistance mutations in HIV-1: March 2013. Available at: http://www.iasusa.org/sites/default/files/tam/21-1-6.pdf. Accessed 1 October 2013.
10. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing firstline antiretroviral therapy. AIDS 2009; 23:1127-34.
11. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44:447-52.
12. Dunn DT, Goodall RL, Munderi P, et al. Residual activity of two HIV antiretroviral regimens prescribed without virological monitoring. Antimicrob Agents Chemother 2011; 55:4575-80.
13. Piketty C, Gerard L, Chazallon C, et al. Virological and immunological impact of non-nucleoside reverse transcriptase inhibitor withdrawal in HIV-infected patients with multiple treatment failures. AIDS 2004; 18: 1469-71.
14. Bacheler LT, Anton ED, Kudish P, et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 2000; 44:2475-84.
15. Aghokeng AF, Kouanfack C, Eymard-Duvernay S, et al. Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in Cameroon. J Int AIDS Soc 2013; 16:18004.
16. Torti C, Pozniak A, Nelson M, Hertogs K, Gazzard BG. Distribution of K103N and/or Y181C HIV-1 mutations by exposure to zidovudine and non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother 2001; 48:113-6.
17. Hanna GJ, Johnson VA, Kuritzkes DR, et al. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J Infect Dis 2000; 181:904-11.
18. Hoffmann CJ, Charalambous S, Sim J, et al. Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin. Infect Dis 2009; 49:1928-35.